Standard BioTools, Inc. (FLDM) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sanara MedTech, Inc.

Cerus Corp.

NeuroPace, Inc.

ZimVie, Inc.

Anika Therapeutics, Inc.

Standard BioTools, Inc.

AVITA Medical, Inc.

Allurion Technologies, Inc.

Accuray, Inc.

Pulse Biosciences, Inc.

Alpha Tau Medical Ltd.

Why is Standard BioTools, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate -44.45% of over the last 5 years

Flat results in Mar 26

INTEREST(9M) At USD 0.01 MM has Grown at inf%
NET SALES(HY) At USD 44.94 MM has Grown at -32.86%
DEBTORS TURNOVER RATIO(HY) Lowest at 2.24 times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -23.88%, its profits have risen by 51.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -23.88% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Standard BioTools, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Standard BioTools, Inc.

-23.88%

-0.95

69.33%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-5.18%

EBIT Growth (5y)

-44.45%

EBIT to Interest (avg)

-41.96

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.55

Sales to Capital Employed (avg)

0.31

Tax Ratio

0.22%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

84.15%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.82

EV to EBIT

-1.69

EV to EBITDA

-1.86

EV to Capital Employed

0.69

EV to Sales

1.59

PEG Ratio

Dividend Yield

ROCE (Latest)

-40.98%

ROE (Latest)

-10.52%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -90.66 MM

NET PROFIT(HY)

Higher at USD 5.07 MM

ROCE(HY)

Highest at -9.86%

CASH AND EQV(HY)

Highest at USD 642.75 MM

DEBT-EQUITY RATIO (HY)

Lowest at -75.86 %

OPERATING PROFIT(Q)

Highest at USD -8.01 MM

OPERATING PROFIT MARGIN(Q)

Highest at -37.87 %

PRE-TAX PROFIT(Q)

Highest at USD -11.54 MM

-19What is not working for the Company

INTEREST(9M)

At USD 0.01 MM has Grown at inf%

NET SALES(HY)

At USD 44.94 MM has Grown at -32.86%

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.24 times

EPS(Q)

Lowest at USD -0.12

Here's what is working for Standard BioTools, Inc.

Net Profit

At USD 5.07 MM has Grown at 109.83%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Profit

Higher at USD 5.07 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Operating Cash Flow

Highest at USD -90.66 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD -8.01 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -37.87 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -11.54 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Cash and Eqv

Highest at USD 642.75 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -75.86 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Standard BioTools, Inc.

Net Sales

At USD 44.94 MM has Grown at -32.86%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Interest

At USD 0.01 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

EPS

Lowest at USD -0.12

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debtors Turnover Ratio

Lowest at 2.24 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio